Cue Biopharma vs Immutep
CUE and IMMP side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CUE and IMMP compare
Cue Biopharma grew revenue faster over the last twelve months (354% versus 134% for Immutep).
Immutep keeps more of each dollar of sales as profit, with a net margin of −328% compared with −436% at Cue Biopharma.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CUE | IMMP |
|---|---|---|
| Size and price | ||
| Market cap | $127M | – |
| Share price | $17.50 | $3.65 |
| Change, 1 year | −14.6% | −89.7% |
| Change, 5 years | −96.1% | −95.2% |
| Beta (5Y) | 2.35 | 1.68 |
| Employees | 29 | 46 |
| StockData Score | ||
| Total score | 8 | 8 |
| Valuation score | 0 | 0 |
| Growth score | 2 | 2 |
| Performance score | 1 | 1 |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 3.4× | – |
| P/B | 55.0× | – |
| FCF yield | −39.5% | – |
| Growth | ||
| Revenue growth (TTM) | 354% (better) | 134% |
| Revenue growth, 5Y average | 54.2% (better) | 43.5% |
| Profitability | ||
| Operating margin | −262% | – |
| Net margin | −436% | −328% (better) |
| FCF margin | −133% (better) | −230% |
| Return on equity | −1603% | −77.3% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 1.25 | 5.69 (better) |
| Altman Z-score | −30.49 | – |
| Piotroski F-score | 5 (better) | 2 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | – |
| Ownership | ||
| Held by institutions | 22.6% | – |
| Held by insiders | 17.4% | 0.89% |
| Insider net buying, 12 months | −$2.3M | – |
| Short interest, % of float | 14.4% | – |
Go deeper
- CUE stock overview
- CUE income statement
- CUE valuation and score
- IMMP stock overview
- IMMP income statement
- IMMP valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.